A review in Nature Medicine outlines strategies to overcome RAS inhibitor resistance, including the investigational RAS(ON) inhibitor doublet daraxonrasib plus zoldonrasib and combinations with biologics like T-DXd or amivantamab. Commentary also centers on transformed EGFR-mutated NSCLC, questioning the relevance of T790M as a transformation risk factor in the era of first-line osimertinib. A new investigator-initiated trial will explore gut microbiome modulation with immunotherapy in NSCLC.
“This support will advance our NSCLC #IIT exploring gut microbiome modulation with #immunotherapy and establish a longitudinal multi-omic biobank.”
— @Jani_Chinmay · Gut microbiome research · View post ↗
“Interesting report on transformed EGFR mutated NSCLC. Question is how these data apply to regions where osimertinib is 1st line therapy, since T790M was risk factor for transformation.”
— @drgandara · Transformed EGFR-mutant NSCLC · View post ↗📌 Amplified by @KolPulseAI
“RAS(ON) inhibitor doublet (daraxonrasib + zoldonrasib) & RTK-targeting biologics (T-DXd, amivantamab) are key combination strategies”
— @HHorinouchi · RAS inhibitor combinations · View post ↗A review of rare histological subtypes of triple-negative breast cancer is being shared, highlighting implications for prognosis and treatment. Separately, the breast oncology community is discussing the psychological impact of denial in patients with Stage IV metastatic breast cancer, noting it can be a harmful defense mechanism.
“Beyond a single disease: review of rare histological subtypes of triple-negative breast cancer with implications for prognosis and treatment”
— @dr_yakupergun · Rare TNBC subtypes · View post ↗
“Denial is a normal psychological defense mechanism, but it can be really harmful and lead patients down the wrong path. I see it every day.”
— @Dr_RShatsky · Patient psychology in MBC · View post ↗📌 Amplified by @KolPulseAI
A study of sequential Nivolumab/Ipilimumab in advanced HCC patients who progressed on first-line Atezolizumab/Bevacizumab showed a 20% ORR and a median duration of response of 23.7 months. Separately, an updated ASTRO guideline for radiation therapy in pancreatic cancer is now in press. Preclinical data also suggest resistance to the investigational RAS(ON) inhibitor daraxonrasib in pancreatic cancer can induce HER2, creating a potential vulnerability to ADCs.
“👉 20% ORR in Ate/Bev-experienced patients. 👉 Durable benefit: 23.7 mo median DoR compared to treatment-naïve cohorts (24.8 mo).”
— @hongjaechon · Nivolumab/Ipilimumab in 2L HCC · View post ↗
“Excited that the updated @ASTRO_org guideline for radiation therapy in #pancreaticcancer is now in press”
— @MikeChuongMD · Pancreatic Cancer RT Guideline · View post ↗
“RAS(ON) inhibition can induce/upregulate cell-surface RTKs, including HER2 in selected models—creating a potential therapeutic vulnerability rather than simply another resistance mechanism.”
— @niklas_kluemper · Daraxonrasib Resistance & ADC Synergy · View post ↗
“Early‐Onset Gastric Cancer as a High‐Risk Disease Entity in the US: Clinicopathologic Features, Regional Variation, and Outcomes”
— @DaniCastilloMD · Early-Onset Gastric Cancer · View post ↗Track oncology’s top KOLs in your specialty
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
- ✓Enhanced KOL profiles
- ✓Pharma influence & potential advisory-board patterns
- ✓2025 Open Payments financial analysis
- ✓Social-media sentiment & trend signals
A study on non-muscle invasive bladder cancer (NMIBC) found a Hybrid 3-Tier grading system improved discrimination for T1+ progression to 0.815 (P<0.001) compared to the current binary low-grade/high-grade system. Commentary also highlights the limitations of ctDNA in renal cell carcinoma, where a negative result cannot yet safely rule out residual disease.
“Maybe grade is a continuum not a binary switch #NMIBC #BladderCancer #UroPath”
— @LauraBukavinaMD · NMIBC Grading · View post ↗
“In low-shedding tumors like RCC, ctDNA+ is informative, but ctDNA− cannot yet safely rule out residual disease.”
— @DrYukselUrun · ctDNA in RCC · View post ↗A proposed CMS memo would eliminate Medicare coverage for autologous stem cell transplant (ASCT) in patients with ISS stage I multiple myeloma, prompting concern as trials like DETERMINATION have shown benefit in this population. Separately, a retrospective French study on home administration of bispecifics teclistamab and elranatamab found no difference in PFS but improved infection-free survival compared to in-clinic administration.
“This is a big deal. ASCT no longer covered for ISS stage I 🤯”
— @RahulBanerjeeMD · CMS ASCT Coverage · View post ↗
“Fascinating 🇫🇷 Hospital-at-Home data for teclistamab/elranatamab in myeloma: no PFS difference, better infection-free survival, patients stay home.”
— @hhashmi87 · Home Administration of Bispecifics · View post ↗“We've often wondered why ataxia / cerebellar AEs happened with RW tal (and TAL-3) but not TAL-1... turns out they were there, just thankfully rare.”
— @RahulBanerjeeMD · Talquetamab AEs · View post ↗First-line epcoritamab combined with bendamustine and rituximab induced sustained remissions beyond 3 years in patients with follicular lymphoma. Discussions are also clarifying risk stratification in CEBPA-mutated AML, highlighting that favorability under ELN 2022 guidelines is driven by an in-frame bZIP mutation, not biallelic status alone.
“First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma”
— @MostafaFaisal14 · Follicular Lymphoma · View post ↗
“✅ Favorability is driven principally by the in-frame bZIP lesion, not biallelic status alone.”
— @abouabdrahman0 · CEBPA-mutated AML · View post ↗
“Genomic profiling reveals molecular heterogeneity in patients with Richter transformation (RT) and chronic lymphocytic leukemia (CLL)”
— @mtmdphd · Richter Transformation · View post ↗